Accenture Ventures completed an investment in Ryght AI.

Accenture Ventures, the corporate venture capital arm of Accenture, completed an investment in Ryght AI, a platform provider supporting the design and execution of clinical research for the life sciences industry. Financial terms were not disclosed. “Generative and agentic AI are transforming the foundation of clinical research. With our investment in Ryght AI, we’re giving our life sciences clients the ability to fully leverage operational and scientific data and bring life-changing therapies to market faster, more efficiently and with greater precision," Petra Jantzer, Accenture Senior Managing Director and Global Lead of Life Sciences.